iSpecimen, Inc. (ISPC)

NASDAQ: ISPC · IEX Real-Time Price · USD
1.65
-0.01 (-0.60%)
At close: Sep 30, 2022 4:00 PM
1.58
-0.07 (-4.24%)
After-hours: Sep 30, 2022 5:30 PM EDT

Company Description

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide.

Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations.

The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them.

It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

iSpecimen, Inc.
iSpecimen logo
Country United States
Founded 2009
IPO Date Jun 17, 2021
Industry Diagnostics & Research
Sector Health Care
Employees 59

Contact Details

Address:
450 Bedford Street
Lexington, MA 02420
United States
Phone 781 301 6700
Website ispecimen.com

Stock Details

Ticker Symbol ISPC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency US Dollars
IPO Price $8.00
CIK Code 1558569
ISIN Number US45032V1089
SIC Code 8731

Key Executives

Name Position
Dr. Christopher J. Ianelli M.D., Ph.D. Founder and Director
Tracy Wilson Curley Chief Financial Officer and Treasurer
Jill Mullan Chief Operating Officer, Secretary and Director
Benjamin Bielak Chief Information Officer
Eric Langlois Senior Vice President of Sales and Business Development
Carly Lejnieks Vice President of Marketing
Emily Hubbard Vice President of Site Management and Development
David Wages M.D., Ph.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Sep 28, 2022 SC 13G Statement of acquisition of beneficial ownership by individuals
Sep 22, 2022 8-K Current Report
Aug 5, 2022 EFFECT Notice of Effectiveness
Aug 5, 2022 424B3 Prospectus
Aug 4, 2022 8-K Current Report
Aug 4, 2022 10-Q Quarterly Report
Jul 29, 2022 S-3 Registration statement under Securities Act of 1933
Jul 12, 2022 EFFECT Notice of Effectiveness
Jul 1, 2022 S-3 Registration statement under Securities Act of 1933
Jun 21, 2022 8-K Current Report